Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?

Dryden, Matthew

doi:10.1097/qco.0000000000000142

Cited by 18 publications

(21 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional antibiotics recommended by guidelines for cSSTI with proven or suspected MRSA involvement include linezolid, daptomycin and tigecycline (Table 2), with 7-14 days of therapy generally being recommended [35,36,38,[40][41][42][43]. Several new antibiotics approved in Europe for the treatment of ABSSSIs (oritavancin, dalbavancin and tedizolid phosphate) [19][20][21] or cSSTI (ceftaroline) [44] are not yet discussed in European guidelines.…”

Section: Management Of Skin and Soft-tissue Infectionsmentioning

confidence: 99%

Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe

Nathwani

Dryden

Garau

2016

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Skin and soft-tissue infections (SSTIs) are a common indication for antibiotic use in Europe and are associated with considerable morbidity. Treatment of SSTIs, occasionally complicated by infection with meticillin-resistant Staphylococcus aureus, can be resource intensive and lead to high healthcare costs. For patients treated in an inpatient setting, once the acute infection has been controlled, a patient may be discharged on suitable oral antibiotic therapy or outpatient parenteral antibiotic therapy. The recently confirmed efficacy of single-dose (e.g. oritavancin) and two-dose (e.g. dalbavancin) infusion therapies as well as tedizolid phosphate, a short-duration therapy available both for intravenous (i.v.) and oral use, for treating SSTIs has highlighted the need for clinicians to re-evaluate their current treatment paradigms. In addition, recent clinical trial data reporting a novel endpoint of early clinical response, defined as change in lesion size at 48-72 h, may be of value in determining which patients are most suitable for early de-escalation of therapy, including switch from i.v. to oral antibiotics, and subsequent early hospital discharge. The aim of this paper is to review the potential impact of assessing clinical response on clinical decision-making in the management of SSTIs in Europe, with a focus on emerging therapies.

show abstract

Section: Management Of Skin and Soft-tissue Infectionsmentioning

confidence: 99%

Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe

Nathwani

Dryden

Garau

2016

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

show abstract

“…Oritavancin, which is active against Gram-positive bacteria, was also recently approved in the USA [46] and the EU [47] for use in adult patients with ABSSSI. Antibacterials from other classes that have recently been approved for use in the treatment of ABSSSI, include drugs with activity against Gram-positive bacteria (daptomycin and tedizolid) and with activity against both Gram-positive and -negative bacteria (ceftaroline and tigecycline) [7].…”

Section: Place Of Dalbavancin In the Management Of Acute Bacterial Skmentioning

confidence: 99%

“…Vancomycin (glycopeptide antibacterial) and teicoplanin (first generation lipoglycopeptide antibacterial, a subclass of the glycopeptides; not approved in USA) have been the mainstay of parenteral antibacterial therapy for serious drug-resistant Gram-positive infections, including methicillin-resistant S. aureus (MRSA) infections [1,[5][6][7]. However, in addition to an increased risk of nephrotoxicity with high doses of vancomycin and the need for therapeutic drug monitoring, its use is potentially limited by the emergence of vancomycin-intermediate and -resistant S. aureus and enterococci strains (albeit these isolates remain relatively uncommon), with vancomycin-resistant isolates associated with treatment failures and poor clinical outcomes [5,6,8].…”

Section: Introductionmentioning

confidence: 99%

Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

Scott

2015

Drugs

View full text Add to dashboard Cite

Intravenous dalbavancin (Dalvance™; Xydalba™) is approved for use in adult patients with acute bacterial skin and skin structure infections (ABSSSI), with the recommended regimen being a 1000 mg dose followed 1 week later by a 500 mg dose. In the multinational DISCOVER 1 and 2 trials in adult patients with ABSSSI, dalbavancin treatment was noninferior to vancomycin (for ≥ 3 days with an option to switch to oral linezolid to complete a 10- to 14-day course) in terms of early clinical success rates (assessed 48-72 h after initiation of treatment; primary endpoint required by the FDA to assess noninferiority in registration trials of ABSSSI). Clinical response rates were also similar in both treatment groups at the end of treatment (day 14-15), irrespective of geographic region or baseline characteristics, including by infection type, diabetes mellitus status, systemic inflammatory response syndrome status, causative pathogen and renal function. Dalbavancin was generally well tolerated, with adverse events generally being of mild to moderate intensity and transient. With its broad spectrum of activity against clinically relevant Gram-positive pathogens and its favourable pharmacokinetic profile that permits a convenient two-dose, once-weekly regimen with no requirement for therapeutic drug monitoring, dalbavancin is a promising emerging option for the treatment of ABSSSI in adult patients.

show abstract

“…Intravenous antibiotics with once daily dosing such as ceftriaxone, teicoplanin and ertapenem are convenient and also have broad-spectrum antimicrobial activity. The recent discovery of novel antibiotics for SSTIs may significantly alter the way OPAT is delivered in the future 29. Oritavancin and dalbavancin are both delivered as a single intravenous infusion and are non-inferior to 7–10 days of daily vancomycin and linezolid 30 31.…”

Section: Discussionmentioning

confidence: 99%

Risk factors for amendment in type, duration and setting of prescribed outpatient parenteral antimicrobial therapy (OPAT) for adult patients with cellulitis: a retrospective cohort study and CART analysis

Quirke

Curran

O’Kelly

et al. 2017

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?

Abstract: There is now a wide range of antibiotics for treating complicated skin and soft tissue infections or acute bacterial skin and skin structure infections, and they all have a role in different clinical scenarios. Use in nonlicensed situations needs to be assessed.

Cited by 18 publications

References 45 publications

Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe

Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe

Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

Risk factors for amendment in type, duration and setting of prescribed outpatient parenteral antimicrobial therapy (OPAT) for adult patients with cellulitis: a retrospective cohort study and CART analysis

Contact Info

Product

Resources

About